{"id":"W2029587541","doi":"10.1111/j.1398-9995.2004.00772.x","title":"Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","year":2004,"lang":"en","type":"article","venue":"Allergy","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":1118,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre for Research in Astrophysics of Québec","funders":"","keywords":"Omalizumab; Medicine; Asthma; Exacerbation; Placebo; Adverse effect; Population; Internal medicine; Pediatrics; Incidence (geometry); Randomized controlled trial; Asthma exacerbations; Intensive care medicine; Immunoglobulin E; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0000691829,0.0004300571,0.000914053,0.0002748375,0.00009789436,0.00002142366,0.0001327139,0.0001494899,0.0007865642],"category_scores_gemma":[0.00002326366,0.0002756129,0.0002252134,0.0004183552,0.0001046621,0.00011933,0.00001775878,0.0001328909,0.0001160125],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00025602,"about_ca_system_score_gemma":0.0003170157,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003506014,"about_ca_topic_score_gemma":0.0002239677,"domain_scores_codex":[0.9980215,0.00008172694,0.0004685524,0.0004681606,0.0005169942,0.0004431023],"domain_scores_gemma":[0.9986643,0.00004387549,0.0003147214,0.0004596394,0.0003246793,0.0001927804],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.2297867,0.03356459,0.3156982,0.0001759773,0.005952331,0.0006715075,0.002667617,0.01218854,0.000345928,0.0009883714,0.002440385,0.3955199],"study_design_scores_gemma":[0.2850803,0.07177247,0.5894902,0.001760666,0.00009270196,0.00002534889,0.0006923139,0.00004360872,0.002064186,0.00001533907,0.04813088,0.0008319893],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9893501,0.005167327,0.000001158415,0.0002309511,0.00005641231,0.001356112,0.00005718891,0.00003755591,0.003743213],"genre_scores_gemma":[0.9945758,0.001506521,0.00004360258,0.0009051736,0.00006050588,0.0001414205,0.00006470958,0.00006691024,0.002635333],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3946879,"threshold_uncertainty_score":0.9999696,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01912305832587868,"score_gpt":0.2339531596340917,"score_spread":0.2148301013082131,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}